Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?
MGP Page, K Bush - Current Opinion in Pharmacology, 2014 - Elsevier
Highlights•Agents targeting resistant Gram-negative bacteria are in the antibacterial
pipeline.•Both broad and narrow spectrum agents are in clinical development.•Public …
pipeline.•Both broad and narrow spectrum agents are in clinical development.•Public …
New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria
AJ O'neill - Expert opinion on investigational drugs, 2008 - Taylor & Francis
Background: Infections caused by multi-drug resistant (MDR) Gram-negative bacteria
represent an ever-growing area of unmet medical need. To address this need, it is …
represent an ever-growing area of unmet medical need. To address this need, it is …
Designing drugs that overcome antibacterial resistance: where do we stand and what should we do?
R Penchovsky, M Traykovska - Expert opinion on drug discovery, 2015 - Taylor & Francis
Introduction: In recent years, infections caused by multidrug-resistant bacterial pathogens
have become a huge issue to public healthcare systems. Indeed, the misuse of antibiotics …
have become a huge issue to public healthcare systems. Indeed, the misuse of antibiotics …
Late stage antibacterial drugs in the clinical pipeline
SJ Projan, PA Bradford - Current opinion in microbiology, 2007 - Elsevier
Bacterial resistance to antimicrobial agents is a growing problem worldwide. Not only is
issue compounded by the fact that there are fewer pharmaceutical companies conducting …
issue compounded by the fact that there are fewer pharmaceutical companies conducting …
Infections by multidrug-resistant Gram-negative Bacteria: What's new in our arsenal and what's in the pipeline?
D Koulenti, A Song, A Ellingboe, MH Abdul-Aziz… - International journal of …, 2019 - Elsevier
The spread of multidrug-resistant bacteria is an ever-growing concern, particularly among
Gram-negative bacteria because of their intrinsic resistance and how quickly they acquire …
Gram-negative bacteria because of their intrinsic resistance and how quickly they acquire …
Will new antimicrobials overcome resistance among Gram-negatives?
M Bassetti, F Ginocchio, M Mikulska… - Expert review of anti …, 2011 - Taylor & Francis
The spread of resistance among Gram-positive and Gram-negative bacteria represents a
growing challenge for the development of new antimicrobials. The pace of antibiotic drug …
growing challenge for the development of new antimicrobials. The pace of antibiotic drug …
Investigational agents for the treatment of Gram-negative bacterial infections: a reality check
K Bush - ACS infectious diseases, 2015 - ACS Publications
Antibiotic-resistant Gram-negative bacteria are, arguably, the most difficult organisms to
treat, with a limited number of new antibiotics in the development pipeline. Currently 24 new …
treat, with a limited number of new antibiotics in the development pipeline. Currently 24 new …
[HTML][HTML] New antibiotics in development target highly resistant gram-negative organisms
T Kish - Pharmacy and Therapeutics, 2018 - ncbi.nlm.nih.gov
New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms - PMC
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Back to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Resistance drives antibacterial drug development
U Theuretzbacher - Current Opinion in Pharmacology, 2011 - Elsevier
New resistance challenges continue to evolve and spread worldwide. In an otherwise
mature field, antibacterial drug development is primarily driven by resistance trends with a …
mature field, antibacterial drug development is primarily driven by resistance trends with a …
Antimicrobial resistance and treatment: an unmet clinical safety need
M Bassetti, A Russo, A Carnelutti… - Expert opinion on drug …, 2018 - Taylor & Francis
Introduction: Infections due to multidrug-resistant (MDR) bacteria are burdened by high
mortality rates. The development of new compounds to face the global threat of resistance is …
mortality rates. The development of new compounds to face the global threat of resistance is …